Containing nitrogen (A61K47/16)

Production and application of bacterial histamine // 2628536
FIELD: medicine.SUBSTANCE: method for selecting a probiotic lactic bacterial strain for use in the local production of histamine in a mammal is provided. A product and composition for the local production of histamine in a mammal containing a lactic acid bacterial strain having an active histidine operon and capable of producing histamine is proposed for use in the treatment and/or prevention of inflammatory conditions.EFFECT: local production of histamine in a mammal by selecting certain strains of lactic acid bacteria.13 cl, 9 dwg, 2 tbl, 5 ex

ethod and improved pharmaceutical composition for acceleration of pde-5 inhibitor transdermal delivery // 2618462
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine and is a transdermal pharmaceutical composition in the form of gel or patch that contains vardenafil, enhancer selected from the group consisting of sodium lauroamphoacetate, quaternium-60, izostearamidopropil morpholine lactate and combinations thereof, and a pharmaceutically acceptable excipient. The enhancer accelerates the kinetics of transdermal absorption of vardenafil. Vardenafil and enhancer are present in the composition in a ratio from 20:1 to 2:1 by weight. The invention also relates to the method of acceleration of the transdermal delivery of vardenafil.EFFECT: invention provides transdermal delivery acceleration due to the vardenafil enhancer.8 cl, 2 ex, 2 dwg
Pharmaceutical composition based on 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine as anti-tumor agent // 2614234
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and includes pharmaceutical composition, which is solution of pharmaceutically acceptable substance 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine of formula (I) and D-mannitol in water. Composition is used for therapy of malignant tumors in human or animal.EFFECT: technical result is obtaining stable, long-term stored solution of Substance 1.1 cl

Nasal drug delivery device // 2612506
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine and medical equipment and can be used for delivery of the composition in an olfactory region of the nasal cavity. Proposed device, comprising a container, diffuser, chamber for composition and nozzle. Container contains a propellant. Diffuser is connected with container and with a chamber for the composition. Nozzle is communicated with chamber for the composition. Disclosed a method using said device for delivery of the composition in an olfactory region of the nasal cavity.EFFECT: invention provides efficient introduction of composition in an olfactory region and its delivery through the blood-brain barrier due to improvement of the delivery mechanism of most part of the atomized drug in the upper part of the nasal cavity to increase exposure in the olfactory epithelium.33 cl, 25 dwg, 4 tbl, 5 ex

ethod for preparation of suspension of metal nanoparticles for external and internal application // 2610171
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry, veterinary, agriculture and represents method for obtaining water-based suspension of copper nanoparticles for external application, characterised by the fact that ultrasonic dispersion of copper nanoparticles is realised for 30 min with frequency 35 Hz with water solution of catholyte with parameters: Eh=-300 mV, pH 7-8, stabilised with amino acid threonine in amount not less than 0.01 wt % at temperature not higher than 40°C.EFFECT: invention makes it possible to obtain in a stably biologically active suspension of preparation of copper nanoparticles, which does not produce toxic effect.3 cl, 2 dwg

Aerosol preparation based on fenoterol hydrobromide for treating respiratory diseases // 2577289
FIELD: medicine.SUBSTANCE: invention refers to medicine and pharmaceutical industry and concerns composition and method of producing the preparation of highly effective pharmaceutical substance and excipients allowing to form a fine particle aerosol to penetrate into the bronchi and pulmonary alveoli. Inhalation formulation for treating bronchial asthma and chronic obstructive pulmonary disease, containing as active component fenoterol hydrobromide, as a solvent-pure ethyl alcohol, a propellant, the propellant contains HFA-134a and/or HFA-227ea, as well as additionally contains an acidity regulator selected from hydrochloric acid, phosphoric and citric acids, as a substance which regulates the distribution profile, triethyl citrate.EFFECT: invention provides higher respirable fraction up to 35-40 % and obtaining optimum distribution profile of particles.2 cl, 1 dwg, 4 ex

Encapsulates // 2574030
FIELD: chemistry.SUBSTANCE: group of the inventions relates to field of delivery of useful agents in consumer goods, namely deals with encapsulate, containing envelope, based on cross-linked polymer, and core, containing material, selected from the group, consisting of fragrance, silicon, biocontrol agent, antimicrobial agent, flavour, warming or cooling agent, medication, sunscreen preparation and their mixtures. Said envelope additionally contains fragment, sensitive to electromagnetic radiation, selected from the group, consisting of visible light, ultraviolet radiation and their mixtures, provided by monomer of structure: . Said encapsulates can be used in various consumer goods.EFFECT: group of inventions provides encapsulates, releasing useful agents under impact of electromagnetic radiation.10 cl, 67 ex, 7 tbl

Pharmaceutical composition for treating mycotic diseases // 2563811
FIELD: medicine.SUBSTANCE: as an active substance, a formulation according to the invention contains 3-ethoxyxycarbonyl-5-(4-chlorobenzylidene)thiazolidine-2,4-dione 2-5 wt %, and also the pharmaceutical composition is expected to contain carbamide in an amount of 2.5-4.0 wt %, as a keratolytic agent. The ointment also contains a lipophilic base that is petroleum paraffin wax in an amount of 5-7 wt %, stearic acid 2-6.5 wt %, emulsion wax 8-12 wt %, a target additive - benzoic acid 0.1-2 wt % and Vaseline oil up to 100%. The pharmaceutical formulation is produced by fusing the solid ingredients of the base, adding concentrated 3-ethoxyxycarbonyl-5-(4-chlorobenzylidene)thiazolidine-2,4-dione in Vaseline oil and carbamide in Vaseline oil.EFFECT: producing the pharmaceutical formulation possessing the high chemotherapeutic efficacy and good tolerance, low toxicity that makes it applicable in treating dermatomycosis of different localisation.2 cl, 3 tbl

ethods, compositions and sets for lyophilisation // 2540480
FIELD: chemistry.SUBSTANCE: invention relates to a method of lyophilisation of a composition, which contains purified antithrombin III (AT III) and a crystallised substance, selected from alanine, mannitol, glycine or NaCl. The claimed method includes freezing the composition at a temperature from -52°C to -60°C for 6-15 hours, annealing the composition at -30°C for 1 hour, re-freezing the composition at a temperature from -52°C to -60°C for 2-15 hours at keeping the product temperature between -48°C and -52.7°C for 4-10 before lyophilisation and drying the composition with obtaining a lyophilised cake. The invention also relates to a pharmaceutical set, which contains the said lyophilised cake and a liquid reagent.EFFECT: invention provides obtaining the lyophilised composition, containing AT III, which preserves its activity and stability.14 cl, 24 dwg, 5 tbl, 2 ex

Composition for transdermal delivery of medications into organism and thereon-based drug form // 2535095
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine. Described is a composition for the transdermal introduction of medications (M) into a human and animal organism, including cases of urgent drug treatment and prevention of acute pathological conditions. The composition consists of a solution of one or several M in a mixture of at least two solvents: dialkylamide of lower carboxylic acid and (or) alkylpyrrolidone and monoterpenes and (or) monoterpenoids. The total volume concentration of N,N-dialkylamides of lower carboxylic acids or N-alkylpyrrolidones constitutes from 1% to 99% of the mixture volume.EFFECT: composition makes it possible to realise urgent drug treatment and prevention of acute pathological conditions of a human and animal organism by a simple in implementation, safe and cheap method.12 cl, 6 dwg, 4 ex

Compounds and formulations for active substance delivery // 2530889
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds or their pharmaceutically acceptable salts which can be applicable for biologically active substances delivery.EFFECT: invention refers to pharmaceutical formulations containing the above compounds, and to a method for administering the biologically active substances.17 cl, 10 tbl, 19 ex
New protective compositions for recombinant factor viii // 2510279
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to medicine, namely to pharmacology and describes a histidine-free pharmaceutical composition containing high-purity factor VIII; arginine and saccharose, a surfactant for the prevention or at least the inhibition of a surface adsorption of factor VIII; 0.5 to 10 mM calcium chloride for the specific stabilisation of factor VIII, and sodium citrate or maleic acid as a pH buffer.EFFECT: invention provides the protective function for preserve high-yield factor VIII over the whole cycle of pharmaceutical processing, long storage and end recovery and administration into the patient.18 cl, 16 tbl, 8 ex

ethod of selecting tactics of treating actinic keratosis // 2495628
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dermatooncology, and can be used in treatment of actinic keratosis. For this purpose foci of disease are identified with further carrying out their US-examination and derma analysis. In case if hypoechogenic zone, occupying from 5% to 30% of entire derma thickness, is present in derma, applications with liquid nitrogen with textile tip are performed. In case if hypoechogenic zone, occupying from 30% to 70% of entire derma thickness, is detected, applications with liquid nitrogen with copper tip or photodynamic therapy with application of photosensitiser are performed. In case if hypoechogenic zone, occupying from 70% to entire derma thickness, is detected, photodynamic therapy with application of photosensitiser is carried out.EFFECT: method makes it possible to select tactics of treating said pathology in the most accurate way basing not only on clinical manifestations of disease, but also due to taking into account proliferative abilities of cells, which excludes necessity of carrying out tissue biopsy.3 dwg, 4 ex

Application of calcitonin for treating rheumatoid arthritis // 2453330
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely rheumatology, and is applicable for preventing and treating rheumatoid arthritis in a patient. That is ensured by the oral administration of a therapeutically effective amount of calcitonin in the free form or in the form of a salt or a delivery agent specified in a group specified in N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2- hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and their pharmaceutically acceptable salts.EFFECT: oral introduction promotes improved absorption, more acceptable pharmacokinetic and pharmacodynamic profile and a smaller degree of calcitonin variability, as compared with the other methods of delivery that provides reduced chondrolysis.8 cl, 2 dwg, 2 tbl, 4 ex

Biguanide-containing medications which facilitate dissolution for peptide delivery // 2433830
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to pharmacy and medicine. Pharmaceutical composition includes mixture of: (a) active macromolecular substance; (b) aromatic alcohol, absoption amplifier, selected from propylgallate, butylated hydroxytotuol (BHT), butylated hydroxyanisole (BHA) and their analogues and derivatives, or their mixtures; and (c) biguanide or its pharmaceutically acceptable salt, capable of increasing solubility of aromatic alcohol, absorption amplifier, in water medium, where aromatic alcohol, absorption amplifier, is present in amount (by weight) greater or equal to amount of active substance. Application in pharmaceutical composition of aromatic alcohol, selected from propylgallate, BHT, BHA and their analogues and derivatives, together with biguanide or its pharmaceutically acceptable salt, capable of increasing solubility of aromatic alcohol in water medium, as amplifier of macromolecule absorption through intestine wall. Method of increasing absorption of active macromolecular substance and method of patient treatment include introduction of claimed composition to patient. Application of active macromolecular substance, selected from insulin, C-peptide, GLP-1 or their mixture; aromatic alcohol, absorption amplifier, selected from propylgallate, butylated hydroxytotuol (BHT), butylated hydroxyanisole (BHA) and their analogues and derivatives, or their mixtures; and biguanide or its pharmaceutically acceptable salt, capable of increasing solubility of aromatic alcohol, absorption amplifier, in water medium, in manufacturing medications for treatment of diabetes, osteoporosis, obesity, cancer, osteoarthritis.EFFECT: group of inventions ensures facilitation of passage of peptides, proteins and other macromolecular substances through intestinal wall for improvements of their bioavailability.27 cl, 3 tbl, 11 ex

Epoprostenol-containing composition and method of its obtaining // 2423130
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to method of obtaining composition, including lyophilised one, containing epoprostenol, which includes obtaining solution of epoprostenol or its salt and arginine and bringing solution pH to more than 12 by addition of potassium hydroxide or sodium hydroxide. Invention also relates to pharmaceutical composition and stable solution for treatment of cardio-vascular diseases, which contain epoprostenol or its salt and arginin and have pH higher than 12. Also described is method of treating patient with cardio-vascular disease, which includes introduction of effective amount of said composition.EFFECT: invention ensures obtaining hemocompatible, stable to microorganisms and stable epoprostenol compositions.46 cl, 30 tbl, 5 ex

Peptide composition containing propylene glycol optimal for manufacturing and application in injection devices // 2421238
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, namely to pharmaceutical compositions containing a peptide and propylene glycol, to methods of preparing such compositions, and also concerns methods of reducing contamination of injection devices by a peptide composition and reducing sediment formation in the production equipment during manufacturing of the peptide composition. The agonist GLP-1 is used as said peptide in the composition.EFFECT: reduced contamination of the injection devices during injection.23 cl, 6 ex, 7 dwg

ethod of programmed stimulation of repair regeneration in suturing line of anastomoses of hollow organs of gastrointestinal tract // 2421225
FIELD: medicine.SUBSTANCE: offered invention refers to medicine, namely to surgery, and can be used for prevention of inconsistency of anastomoses of hollow organs in gastrointestinal tract surgery. That is ensured by the oral introduction of 5-oxymethyluracil pills of the weight 1.5 g and diameter 7-7.5 mm on the 2nd postoperative day in the following proportions: 5-oxymethyluracil - 0.5 g, 5 % spirit-acetone acetylphthalylcellulose - 3 layers, 10 % hexane solution of low-molecular polyethylene - 1-3 layers, biological adhesive Sulphacrylate - 1-3 layers.EFFECT: introduction of 5-oxymethyluracil in said dosage form provides stimulation of repair regeneration ensured by selective maximum concentration of the preparation in gastrointestinal segments where the anastomosis has been created, and reduced ischemic disorders.1 ex, 1 dwg

Chrysophanol conjugate, synthesis method thereof, use thereof as medicinal agent for treating diabetic nephropathy, intestinal adhesion, osteoarthritis // 2416596
FIELD: chemistry.SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.8 cl, 4 dwg, 57 ex, 18 tbl

Compositions and mixtures for delivery of active agents // 2403237
FIELD: medicine.SUBSTANCE: invention relates to compounds or their pharmaceutically acceptable salts for delivery of biologically active substances such as amilin, antigens, antimicrobial, anti-migraine and antiviral medications, atrial natriuretic factor, biphosphonates, calcitonite, cholecystokinin, etc., as well as to compositions based on them.EFFECT: extension composition application range.11 cl, 10 tbl, 19 ex
Phospholipid suspension containing dihydroquercetin and method for producing // 2369383
FIELD: medicine.SUBSTANCE: phospholipid suspension contains dihydroquercetin, at least one membrane-forming phospholipid, glycine and water solution of ethyl alcohol with 0.05 to 20% of spirit. To produce phospholipid suspension the following should be performed: dihydroquercetin and phospholipid solution in ethyl alcohol and dispersive medium comprising glycine solution in deionised water. Dispersive medium shall be brought to rotation till stable rotation swirl is obtained, then dihydroquercetin solution shall be added to the rotation swirl and the obtained mixture is to be divided into concentrate of disperse phase and disperse medium.EFFECT: invention enables to increase stability and extend the period of suspension storage, increase bioavailability and selectiveness of active compound exposure.13 cl, 7 ex

Amino acid diamides which are not α-diamides, useful as adjuvants for administration of biologically active agents // 2368599
FIELD: chemistry.SUBSTANCE: invention relates to amino acid diamides which are not α-diamides with formula (1) , where R1 is chosen from a group consisting of functional groups: alkyl, halogen, NO2, OH, OCH3, present separately or in combination, and R2 is H, which are useful as adjuvants for administration of biologically active agents and to pharmaceutical compositions, containing the said diamides with formula (1).EFFECT: increased effectiveness.9 cl, 3 dwg, 1 tbl, 22 ex

Pharmaceutical water-soluble formulation from active principle in form of n-carbamoyl-methyl-4-phenyl-2-pyrrolidone and at least one auxiliary neutral organic low-molecular component and methods of its preparation // 2347565
FIELD: medicine; pharmacology.SUBSTANCE: formulation contains N-carbamoyl-methyl-4-phenyl-2-pyrrolidone as active principle and solubilising neutral organic component selected from the group that comprises diamide of carbonic acid, and/or monosaccharides, and/or disaccharides, and/or polyatomic spirits or their homogeneous mixture, with mass relation of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone and specified solubilising component 1:(0.15-5). Method for preparation of pharmaceutical formulation consists in the fact that formulation components are simultaneously and separately evaporated in depressurised gas medium, and produced vapors are cocondensated on the surface of sedimentation cooled down to negative temperature. The second version of method for preparation of pharmaceutical formulation consists in the fact that formulation components are previously dissolved in water, solution is frozen to the temperature of not higher than - 60°C, then frozen solution is sublimated in depressurised gas medium, and adsorbed water remainder is removed in prepared pharmaceutical formulation. Invention provides for preparation of water-soluble pharmaceutical formulation on the basis of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone.EFFECT: formulation is suitable for preparation of injection, suspension dosage forms.3 cl, 8 dwg, 4 ex
Lyophilised compositions cci-779 // 2345772
FIELD: medicine; pharmacology.SUBSTANCE: lyophilised preparation forms and solutions CCI-779 are available for production of lyophilised preparation forms CCI-779. The specified solutions consist of CCI-779 and solvent chosen from dimethylsulfoxide, acetonitrile, ethanol, isopropanol, tert-butyl alcohol and their mixtures. Besides, methods of lyophilised preparation forms CCI-779 preparation and restoration are offered.EFFECT: improved storage stability and preservation of initial activity.21 cl, 10 ex

Compounds for delivery of active agents // 2326110
FIELD: chemistry.SUBSTANCE: invention pertains to 4-[(4-chloro-2-hydroxybenzoyl)amino]oleic acid, its salts and solvates (formula I), meant for use in compounds and standard dosage states for delivering active agents. The compound for delivering active agents is obtained through mixing (A) at least one active agent, (B) compounds with formula I and extra addition (C) of a solvent. The active agent can be insulin, human growth hormone, recombinant human growth hormone, sodium cromolyn, heparin, calcitonin, parathyroid hormone, as well as a chemically active agent and its combinations, chosen from a group, consisting of a biologically active agent. The active agent is given to the animal in need of the agent through oral administration of a mixture or solid dosage form for oral administration, consisting of formula (I) compounds. The biologically active agent is given to the animal through oral administration of a mixture containing a formula I compound and the biologically active agent.EFFECT: compound for delivery of biologically or chemically active agents to a target.45 cl, 5 tbl, 5 ex

Compositions for bisphosphonates delivery // 2309945
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to compositions used for delivery of bisphosphonate to a target and to development of simple and inexpensive compositions for delivery of bisphosphonates. Invention proposes variants of compositions containing at least one bisphosphonate and at least one compound as a delivery agent. Proposed compositions promote to delivery of bisphosphonates to chosen biological systems and improve bioavailability of bisphosphonates as compared with their administration without compound - a delivery agent. Also, invention proposes a method for preparing the claimed composition, standard medicinal formulation using the claimed composition and a method for administration of bisphosphonates in animal.EFFECT: improved properties of compositions.48 cl, 5 tbl, 9 ex
Injection medicinal formulation for treatment and prophylaxis of blood-parasitic and invasion diseases // 2296568
FIELD: veterinary medicine, pharmacology.SUBSTANCE: invention represents injection antiparasitic medicinal agent containing diminazene salts as an active substance and can be used in treatment and prophylaxis of parasitic diseases. Injection medicinal formulation used for treatment and prophylaxis of blood-parasitic and invasion diseases and comprising diminazene as an active substance, organic solvent, stabilizing agent and preserving agent involves additionally a surface-active substance as a solubilizing agent and distilled water as a co-solvent and wherein poly-(1-vinyl-2-pyrrolidone) is used as a stabilizing agent wherein components are taken in the following content, wt.-%: active substance, 1-20; organic solvent, 10-50; co-solubilizing agent, 1-20; stabilizing agent, 1-20; preserving agent, 0.01-1, and co-solvent, up to 100. Proposed medicinal formulation comprises diminazene benzoate or diminazene adipate, or diminazene nicotinate as an active substance. "Cremofor EL" or "Cremofor ELP" (polyoxyethylene-glycerol-trihydroxystearate), or "Tween-80" (polyoxyethylene sorbitan monooleate), or "Solutol HS15" (polyethylene glycol-660 12-hydroxystearate) are used as a co-solubilizing agent. "Collidon 12PF" or "Collidon 17PF" [poly-(1-vinyl-2-pyrrolidone)] are used as a stabilizing agent. Dimethylacetamide or 1-methyl-2-pyrrolidone or "Solufor P" (2-pyrrolidone), or transcutol, or propylene glycol, or ethylene glycol, or glyceroformal, or dimethylsulfoxide are used as a solvent. The proposed injection medicinal formulation comprises additionally phenazone as active substance in the amount 1-10 wt.-%. Invention provides enhancing stability and activity and decreasing toxicity of the medicinal formulation.EFFECT: improved and valuable properties of formulation.3 cl, 12 ex

Amplifiers absorption for pharmaceutical compositions for local application // 2165265
The invention relates to the development of safe and effective tools that increase the speed of delivery of physiologically active agents through the skin or mucous membrane of the mouth

Pharmaceutical compositions of therapeutic anti-inflammatory and analgesic agent for the local application and the method of production thereof // 2157689
The invention relates to the field of medicine and new therapeutic anti-inflammatory and pain management pharmaceutical compositions containing nimesulide, which is N-(4-nitro, 2-phenoxyphenyl)methanesulfonamide for percutaneous introduction, and method of its manufacture

Anti-inflammatory medication for external use // 2157683
The invention relates to an anti-inflammatory drug for external use, comprising as active ingredient nimesulide
Pharmaceutical composition with analgesic and method of reception // 2141845
The invention relates to medicine, in particular to pharmaceutical compositions for intramuscular injection
 
2551269.
Up!